Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

Theratechnologies Inc.

Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for HIV, nonalcoholic steatohepatitis (NASH), and oncology.

Theratechnologies Inc. | 13,139 followers on LinkedIn. Health innovation that matters | #HIV #NASH #Oncology | Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies.
We currently market prescription products for people with HIV in the United States. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology.

Founder/CEO @ TRESTLE Compliance | Global Compliance Expert, Speaker and Author

L. Stephan Vincze

Vice President of US Commercial Operations at Theratechnologies Inc.

Peter Kowal

Kim Perkins

Álvaro Cardona

En ce jour du Souvenir, nous rendons hommage à ceux qui ont servi et qui continuent de défendre une société pacifique et libre. À 11 heures, nous nous unissons en tant que Canadiens pour observer deux minutes de silence à la mémoire de ceux qui ont fait le sacrifice ultime et qui ont donné leur vie pour nos libertés. Les coquelicots rouges figurent à l'origine dans le poème Au champ d'honneur (1915) du médecin canadien lieutenant-colonel John McCrae, en référence aux coquelicots qui poussaient le long du front occidental pendant la Première Guerre mondiale. Le coquelicot rouge reste aujourd'hui encore un symbole durable du souvenir. #JourduSouvenir __ This Remembrance Day, we honour those who have served and continue to defend a peaceful and free society. At 11 AM, we join together as Canadians in observing two minutes of silence to remember those who made the ultimate sacrifice and gave their lives for our freedoms. Red poppies were originally featured in Canadian physician Lieutenant-Colonel John McCrae’s poem In Flanders Fields (1915), in reference to the poppies which grew along the Western Front during the First World War. The red poppy remains an enduring symbol of remembrance to this day. #RemembranceDay

This Veterans Day, we celebrate and honor America’s veterans for their patriotism, love of country, and willingness to serve and sacrifice for the common good. Theratechnologies salutes veterans for their sacrifices and the values they fought for and continue to safeguard. #VeteransDay #SupportOurVeterans

Great opportunity to meet our team in Indianapolis 🇺🇸 and learn more about Theratechnologies’ commitment to people with HIV. #ANAC2024

Don’t miss what is certain to be an amazing session with Thera’s Mable Taplin RN, MSN this weekend in Scottsdale, Arizona at the Women of Color in Pharma (WOCIP) annual conference. Learn more ⬇️⬇️⬇️

For more than 20 years, #NationalLatinxAIDSAwarenessDay (NLAAD) has been an opportunity to help address the disproportionate impact of #HIV on Hispanic/Latinx communities by promoting HIV testing and treatment and working to end stigma. This year’s focus is to promote treatment among people living with HIV. Representing only 19% of the U.S. population, Hispanic/Latinx people accounted for 32% of the 37,891 new HIV diagnoses in 2022, according to the CDC. This percentage continuously increases year after year. Hear about what drives Luis Alberto Mares Yáñez , Director of Community Mobilization @ Latino Commission on AIDS to do incredible work! 🔽 🔽 🔽 At Theratechnologies, we aim to make a tangible difference by bridging education, advocacy, and clinical care to pave the way for better health outcomes among communities impacted by HIV. #NLAAD #HIVawareness #StopHIVTogether

For more than 20 years, #NationalLatinxAIDSAwarenessDay (NLAAD) has been an opportunity to help address the disproportionate impact of #HIV on Hispanic/Latinx communities by promoting HIV testing and treatment and working to end stigma. This year’s focus is to promote treatment among people living with HIV. Representing only 19% of the U.S. population, Hispanic/Latinx people accounted for 32% of the 37,891 new HIV diagnoses in 2022, according to the CDC. This percentage continuously increases year after year. At Theratechnologies, we aim to make a tangible difference by bridging education, advocacy, and clinical care to pave the way for better health outcomes among communities impacted by HIV. Learn more about NLAAD and sign up for webinars hosted by @ Latino Commission on AIDS ⏩ https://lnkd.in/gumKV_aT #NLAAD #HIVawareness #StopHIVTogether

🍁 La tradition de l' #Actiondegrâcecanadienne est un moment joyeux où l'on réunit la famille et les amis pour célébrer la récolte d'automne et exprimer notre gratitude pour les bienfaits dont nous bénéficions. Joyeuse Action de grâce à tous ceux qui la célèbrent ce long week-end ! 🍁 The tradition of #CanadianThanksgiving is a joyous time to gather family and friends to mark the fall harvest and express gratitude for our blessings. Happy Thanksgiving to all who are celebrating this long weekend!

📈 Today we reported strong financial results and announced positive net income for the third quarter of 2024. To learn more ▶ Read the full press release: https://lnkd.in/edH4Q4uq ▶ Listen to the replay of our earnings call: https://lnkd.in/eKnjxSTD #financialresults #Q32024 #earnings Paul Levesque Philippe Dubuc Christian Marsolais John Leasure

📈 Aujourd'hui nous avons présenté de solides résultats financiers et annoncé un résultat net positif pour le troisième trimestre de l’exercice 2024. Pour en savoir plus: ▶ Consultez notre communiqué de presse : https://lnkd.in/eSi-fJPR ▶ Écoutez le résumé de notre conférence téléphonique : https://lnkd.in/eE4TJefy #résultatsfinanciers #troisièmetrimestre #T32024 Paul Levesque Philippe Dubuc John Leasure Christian Marsolais

We’re heading to Los Angeles for IDWeek 2024, October 16-19, to present three posters on important medical issues facing people with HIV: 🎯 Impact of Tesamorelin on Cardiovascular Disease Risk Prediction Scores in Phase 3 Studies Treatment Arms: Subanalysis 🎯 Cardiovascular Risk Scores and Insulin Resistance are Higher with Excess Visceral Abdominal Fat in People with HIV in the Modern Antiretroviral (ART) Era 🎯 A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes with and without Ibalizumab in a Real-World Setting: United States (PROMISE-US) Study Design and Baseline Characteristics See presentations details here 🔽 #IDWeek2024 #tesamorelin #ibalizumab #MDR #HIVresearch

	Nov '13	Nov '14	Nov '15	Nov '16	Nov '17	Nov '18	Nov '19	Nov '20	Nov '21	Nov '22	Nov '23
revenue							63.22M -	66.05M 4.49%	69.82M 5.71%	80.06M 14.66%	81.76M 2.13%
cost of revenue							26.08M -	26.90M 3.17%	23.26M 13.54%	26.28M 12.98%	19.64M 25.28%
gross profit							37.14M -	39.15M 5.41%	46.56M 18.93%	53.78M 15.50%	62.13M 15.53%
selling and marketing expenses							26.48M -	26.86M 1.42%	28.91M 7.63%	39.39M 36.26%	26.77M 32.04%
general and administrative expenses							8.33M -	12.23M 46.82%	14.62M 19.51%	17.36M 18.75%	15.62M 10.02%
selling general and administrative expenses							34.81M -	39.09M 12.29%	43.52M 11.35%	56.75M 30.38%	42.39M 25.31%
research and development expenses							10.84M -	18.02M 66.21%	28.27M 56.91%	36.94M 30.65%	30.37M 17.78%
other expenses		-2.71M -	1.42M 152.63%	1.49M 4.85%	1.53M 2.37%	-0.00 100.00%
cost and expenses							71.73M -	84.01M 17.12%	95.06M 13.15%	119.97M 26.20%	92.39M 22.99%
operating expenses	10.77M -	11.38M 5.66%	16.37M 43.82%	19.71M 20.39%	33.95M 72.28%	34.54M 1.75%	45.65M 32.17%	57.11M 25.09%	71.80M 25.72%	93.69M 30.48%	72.76M 22.34%
interest expense							4.99M -	5.36M 7.45%	5.66M 5.63%	6.50M 14.71%	10.36M 59.47%
ebitda							40K -	-9.18M 23,045%	-16.32M 77.86%	-27.16M 66.36%	-7.54M 72.24%
operating income							-7.46M -	-17.96M 140.87%	-25.24M 40.54%	-39.91M 58.14%	-10.63M 73.37%
depreciation and amortization							7.50M -	8.78M 17.13%	8.91M 1.51%	12.75M 43.09%	3.31M 74.00%
total other income expenses net							-5.04M -	-4.69M 6.88%	-6.43M 36.90%	-6.89M 7.16%	-2.32M 66.29%
income before tax							-12.50M -	-22.65M 81.27%	-31.66M 39.78%	-46.79M 47.79%	-23.54M 49.70%
income tax expense							4.99M -	16K 99.68%	63K 293.75%	443K 603.17%	421K 4.97%
net income	-3.82M -	-9.20M 140.94%	1.17M 112.77%	305.16K 74.03%	-14.34M 4,798.06%	-4.53M 68.41%	-17.49M 286.12%	-22.67M 29.63%	-31.73M 39.96%	-47.24M 48.90%	-23.96M 49.28%
weighted average shs out	61.01M -	61.01M 0%	62.49M 2.42%	65.81M 5.32%	73.47M 11.63%	75.94M 3.37%	76.93M 1.30%	76.99M 0.08%	92.35M 19.95%	95.25M 3.14%	26.33M 72.36%
weighted average shs out dil	61.01M -	61.01M 0%	63.17M 3.54%	66.60M 5.42%	73.47M 10.32%	75.94M 3.37%	76.93M 1.30%	76.99M 0.08%	92.35M 19.95%	95.25M 3.14%	26.33M 72.36%
eps	-0.06 -	-0.15 139.62%	0.02 114.93%	0.01 66.96%	-0.20 2,802.70%	-0.06 70.20%	-0.23 285.91%	-0.29 26.09%	-0.34 17.24%	-0.50 47.06%	-0.91 82%
epsdiluted	-0.06 -	-0.15 139.62%	0.01 110.00%	0.01 50.67%	-0.20 2,802.70%	-0.06 70.20%	-0.23 285.91%	-0.29 26.09%	-0.34 17.24%	-0.50 47.06%	-0.91 82%

TH

COM:THERATECH

Theratechnologies Inc.

Last Close

1.68

22/11 20:59

Market Cap

97.04M

Beta: -

Volume Today

8.12K

Avg: -

Preview